Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

Topic: Gut, metabolism and diet

Type 2 diabetes is a risk factor in the development of Alzheimer's disease (AD). It has been shown that insulin signalling is desensitised in the brains of AD patients. The incretin hormone Glucagon-like peptide-1 (GLP-1) facilitates insulin signalling, and long-lasting analogues such as liraglutide (Victoza(®)) are on the market as type 2 diabetes treatments. We have previously shown that liraglutide improved cognitive function, reduced amyloid plaque deposition, inflammation, overall APP and oligomer levels and enhanced LTP when injected peripherally for two months in 7 month old APPswe/PS1ΔE9 (APP/PS1) mice. This showed that liraglutide has preventive effects at the early stage of AD development. The current study investigated whether Liraglutide would have restorative effects in late-stage Alzheimer's disease in mice. Accordingly, 14-month-old APP/PS1 and littermate control mice were injected with Liraglutide (25 nmol/kg bw) ip. for 2 months. Spatial memory was improved by Liraglutide-treatment in APP/PS1 mice compared with APP/PS1 saline-treated mice. Overall plaque load was reduced by 33%, and inflammation reduced by 30%, while neuronal progenitor cell count in the dentate gyrus was increased by 50%. LTP was significantly enhanced in APP/PS1 liraglutide-treated mice compared with APP/PS1 saline mice, corroborated with increased synapse numbers in hippocampus and cortex. Total brain APP and beta-amyloid oligomer levels were reduced in Liraglutide-treated APP/PS1 mice while IDE levels were increased. These results demonstrate that Liraglutide not only has preventive properties, but also can reverse some of the key pathological hallmarks of AD. Liraglutide is now being tested in clinical trials in AD patients. This article is part of the Special Issue entitled 'The Synaptic Basis of Neurodegenerative Disorders'.

Key findings

• It has been shown that insulin signalling is desensitised in the brains of AD patients.
• We have previously shown that liraglutide improved cognitive function, reduced amyloid plaque deposition, inflammation, overall APP and oligomer levels and enhanced LTP when injected peripherally for two months in 7 month old APPswe/PS1ΔE9 (APP/PS1) mice.
• This showed that liraglutide has preventive effects at the early stage of AD development.
• Spatial memory was improved by Liraglutide-treatment in APP/PS1 mice compared with APP/PS1 saline-treated mice.
• Overall plaque load was reduced by 33%, and inflammation reduced by 30%, while neuronal progenitor cell count in the dentate gyrus was increased by 50%.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Effect sizereduced by 33%; reduced by 30%; increased by 50%
• Evidence strengthLow

Read the original

• DOI: 10.1016/j.neuropharm.2013.08.005
• PubMed: 23973293
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{mcclean2014-23973293,
  author  = {McClean, P. L. and Hölscher, C.},
  title   = {{Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease}},
  journal = {Neuropharmacology},
  year    = {2014},
  doi     = {10.1016/j.neuropharm.2013.08.005},
  pmid    = {23973293},
  url     = {https://doi.org/10.1016/j.neuropharm.2013.08.005}
}

Related studies in Drug development

• Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice Behavioural brain research · 2015-07-20 · usefulness score 36/100
• Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice Brain, behavior, and immunity · 2017-12-15 · usefulness score 38/100
• Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease PLoS ONE · 2016-07-15 · usefulness score 40/100
• The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease Neuroscience · 2012-10-26 · usefulness score 36/100
• Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice Neurochemical research · 2017-04-06 · usefulness score 38/100
• The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease The Journal of pathology · 2018-04-02 · usefulness score 41/100

Also tagged “agonists”

285 studies in the library carry the topic tag “agonists”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 285 tagged studies.

• Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes Proceedings of the National Academy of Sciences · 2010-03-15 · usefulness score 40/100 · Vascular contributions
• Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease Biochemical Society transactions · 2011-08-01 · usefulness score 36/100 · Drug development
• Neurotrophic and Neuroregenerative Effects of GH/IGF1 International journal of molecular sciences · 2017-11-17 · usefulness score 41/100 · Costs and economics

Similar studies

• Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease 2014 · Drug development
• Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer’s Disease and Type 2 Diabetes 2021 · Drug development
• The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease 2015 · Drug development
• Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats 2013 · Drug development
• Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model 2016 · Drug development
• Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease 2018 · Drug development

More on Drug development

• A review that covers this ground Statin-associated memory loss: analysis of 60 case reports and review of the literature Pharmacotherapy · 2003-07-01 · usefulness score 71/100
• Newest in this subject The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration Metabolism: clinical and experimental · 2026-10-30 · Peer-reviewed · usefulness score 45/100
• Newest in this subject Effect of Metformin on tau pathology and proteostasis in cellular and a Drosophila model of Tauopathy Research Square · 2026-10-29 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Drug development →